<DOC>
	<DOCNO>NCT02607371</DOCNO>
	<brief_summary>The main research question patient survey ass AF ( Atrial Fibrillation ) patient ' preference associate different attribute describe different available anticoagulation treatment option ( Vitamin K Antagonists [ VKA ] New Oral Anticoagulants [ NOACs ] , case NOACs , Apixaban , Dabigatran , Edoxaban Rivaroxaban ) . VKAs ( Marcoumar® , Sintrom ® ) group together compare Rivaroxaban .</brief_summary>
	<brief_title>Anticoagulation Preference AF Patients Study</brief_title>
	<detailed_description>The objective study investigate follow research question cross-sectional survey German-speaking Swiss AF patient treat either VKA NOAC : - Which attribute medication prevent stroke AF patient view important ? - Do AF patient preference regard attribute medication option VKA NOAC , case NOACs , regard rivaroxaban attribute ? - Are subgroups AF patient whose preference one medication option appear average ? - What quality life Swiss German-speaking AF patient ? Are subgroups difference quality life ( example : subgroups patient different CHA2DS2-VASc score ) ? - Which burden German-speaking Swiss AF patient experience association anticoagulation therapy ? Are differences burden treatment ( ACTS ) patient treat VKA NOACs ?</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion AF patient NOAC VKA group : Patients confirm diagnosis nonvalvular atrial fibrillation ( persistent , paroxysmal , permanent ) , Age least 18 year time study inclusion , Generally willingness ( informed consent ) ability fill survey satisfaction treatment quality life , conduct structure phone interview ( approx . 20 30 min ) German language . Additional inclusion criterion Group 1 ( NOAC ) : Continuous anticoagulation either Apixaban , Dabigatran Rivaroxaban prevention Stroke &amp; systemic embolism least previous 3 month . Additional inclusion criterion Group 2 ( VKA ) : Continuous anticoagulation VKA prevention Stroke &amp; systemic embolism least previous 3 month . Exclusion criterion group : Participation another study ( clinical intervention / observational ) within 3 month prior enrollment , Interruption VKA/NOAC therapy 2 week ( bridge ) within prior 3 month plan bridge 4 week study inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Patient treatment preference</keyword>
	<keyword>Non-valvular Atrial Fibrillation</keyword>
	<keyword>NOAC</keyword>
	<keyword>VKA</keyword>
</DOC>